Packages of care for schizophrenia in low- and middle-income countries

PLoS Medicine

Volumn 6, Issue 10, 2009, Pages

  Mari, Jair De Jesus ^a,b   Razzouk, Denise ^a   Thara, Rangaswamy ^c   Eaton, Julian ^d   Thornicroft, Graham ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SCHIZOPHRENIA RESEARCH FOUNDATION   (India)

^d CBM International   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROMETHAZINE; RISPERIDONE;

CLINICAL TRIAL; COGNITIVE THERAPY; HEALTH CARE DELIVERY; HUMAN; META ANALYSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; ARTICLE; DEVELOPING COUNTRY; MENTAL HEALTH SERVICE; OUTCOME ASSESSMENT; STANDARD; STATISTICS; UTILIZATION REVIEW;

COMMUNITY MENTAL HEALTH SERVICES; DEVELOPING COUNTRIES; HUMANS; MENTAL HEALTH SERVICES; OUTCOME ASSESSMENT (HEALTH CARE); SCHIZOPHRENIA;

EID: 70449103208     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000165     Document Type: Review

References (103)

1. World Health Organization (1992) The ICD-10 Classification of Mental and Behavioral Disorders. Geneva: WHO, Available: http://www.who.int/ classifications/apps/icd/icd10online/. Accessed 1 August 2009.
2. McGrath J, Saha S, Welham J, El SO, MacCauley C, et al. (2004) A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2: 13. (Pubitemid 39111865)
3. Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2: e141. doi:10.1371/journal.pmed.0020141.
4. McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30: 67-76.
5. Aleman A, Kahn RS, Selten JP (2003) Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 60: 565-571. (Pubitemid 36682313)
6. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64: 1123-1131.
7. Newcomer JW, Hennekens CH (2007) Severe mental illness and risk of cardiovascular disease. JAMA 298: 1794-1796. (Pubitemid 47598448)
8. Newcomer JW (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 Suppl 4: 8-13. (Pubitemid 46762118)
9. Ran MS, Chen EY, Conwell Y, Chan CL, Yip PS, et al. (2007) Mortality in people with schizophrenia in rural China: 10-year cohort study. Br J Psychiatry 190: 237-242. (Pubitemid 46384008)
10. Brown S (1997) Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171: 502-508.
11. Hyman SE, Chisholm D, Kessler RC, Patel V, Whiteford H (2006) Mental disorders. Jamision D, Breman JG, Measham A, Alleyne G, Claeson M, et al. eds. Disease control priorities in developing countries. New York: Oxford University Press. pp 605-626.
12. Jacob KS, Sharan P, Mirza I, Garrido-Cumbrera M, Seedat S, et al. (2007) Mental health systems in countries: where are we now? Lancet 370: 1061-1077.
13. Kohn R, Saxena S, Levav I, Saraceno B (2004) Treatment gap in mental health care. Bull World Health Organ 82: 858-866. (Pubitemid 39573744)
14. Patel V, Farooq S, Thara R (2007) What is the best approach to treating schizophrenia in developing countries? PLoS Med 4: e159. doi:10.1371/journal. pmed.0040159.
15. Oosthuizen RAP, Emsley, Keyter N, Niehaus DJH, Koen L (2004) Duration of untreated psychosis and outcome in first-episode psychosis. Perspective from a developing country. Acta Psychiatr Scand 111: 214-219.
16. Farooq S, Large M, Nielssen O, Waheed W (2009) The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis. Schizophr Res 109: 15-23.
17. McGlashan TH (1998) Early detection and intervention of schizophrenia: rationale and research. Br J Psychiatry Suppl 172: 3-6. (Pubitemid 28258891)
18. Larsen TK, Friis S, Haahr U, Joa I, Johannessen JO, et al. (2001) Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand 103: 323-334. (Pubitemid 32436745)
19. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, et al. (2003) Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 60: 21-32.
20. Salokangas RK, McGlashan TH (2008) Early detection and intervention of psychosis. A review. Nord J Psychiatry 62: 92-105.
21. Marshall M, Rathbone J (2006) Early intervention for psychosis. Cochrane Database Syst Rev 4: CD004718.
22. Killackey E, Yung AR (2007) Effectiveness of early intervention in psychosis. Curr Opin Psychiatry 20: 121-125.
23. Cassidy CM, Schmitz N, Norman R, Manchanda R, Malla A (2008) Long-term effects of a community intervention for early identification of first-episode psychosis. Acta Psychiatr Scand 117: 440-448. (Pubitemid 351678476)
24. Fitzgerald PB (2001) The role of early warning symptoms in the detection and prevention of relapse in schizophrenia. Aust N Z J Psychiatry 35: 758-764. (Pubitemid 34048446)
25. Drake RJ, Lewis SW (2005) Early detection of schizophrenia. Curr Opin Psychiatry 18: 147-150.
26. Melle I, Johannesen JO, Friis S, Haahr U, Joa I, et al. (2006) Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 163: 800-804. (Pubitemid 44464526)
27. Hafner H, Maurer K (2006) Early detection of schizophrenia: current evidence and future perspectives. World Psychiatry 5: 130-138.
28. Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, et al. (1986) Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med 16: 909-928. (Pubitemid 17214674)
29. Cohen A, Patel V, Thara R, Gureje O (2008) Questioning an axiom: better prognosis for schizophrenia in the developing world? Schizophr Bull 34: 229-244.
30. Eaton J, Agomoh AO (2008) Developing mental health services in Nigeria : the impact of a community-based mental health awareness programme. Soc Psychiatry Psychiatr Epidemiol 43: 552-558.
31. Chatterjee S, Patel V, Chatterjee A, Weiss HA (2003) Evaluation of a community-based rehabilitation model for chronic schizophrenia in rural India. Br J Psychiatry 182: 57-62. (Pubitemid 36132420)
32. Chatterjee S, Pilai A, Jain S, Cohen A, Patel V (2009) Outcomes of people with psychotic disorders in a community-based rehabilitation programme in rural India. Brit J Psychiatry. In press.
33. Rummel C, Hamann J, Kissling W, Leucht S (2003) New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 4: CD004410.
34. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, et al. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085-1097.
35. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, et al. (2007) Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68: 1763-1774.
36. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, et al. (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28: 995-1003.
37. Thornley B, Rathbone J, Adams CE, Awad G (2003) Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2: CD000284.
38. Joy CB, Adams CE, Lawrie SM (2006) Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 4: CD003082.
39. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14: 429-447.
40. Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321: 1371-1376.
41. Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
42. Silva de Lima M, de Jesus Mari J, Breier A, Maria Costa A, Pondé de Sena E, et al. (2005) Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry 66: 831-838. (Pubitemid 41032823)
43. Mari JJ, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, et al. (2004) The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci 254: 356-361. (Pubitemid 40192989)
44. Leucht S, Corves C, Arbter D, Engel RR, Li C, et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41.
45. Huf G, Alexander J, Allen MH, Raveendran NS (2009) Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 8: CD005146.
46. Raveendran NS, Tharyan P, Alexander J, Adams CE, TREC-India II Collaborative Group (2007) Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 335: 865. (Pubitemid 350069461)
47. Huf G, Coutinho ES, Adams CE, TREC Collaborative Group (2007) Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 335: 869.
48. Adams CE, Fenton MK, Quraishi S, David AS (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179: 290-299. (Pubitemid 32996037)
49. David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J (2005) Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev 1: CD000307.
50. Brown GW, Carstairs GM, Wing JK (1962) Influence of family life on the course of schizophrenic illness. Br J Prev Soc Med 16: 55-68.
51. Leff J, Kuipers L, Berkowitz R, Sturgeon D (1985) A controlled trial of social intervention in the families of schizophrenic patients: two year follow-up. Br J Psychiatry 146: 594-600. (Pubitemid 15082061)
52. Pharoah F, Mari J, Rathbone J, Wong W (2006) Family intervention for schizophrenia. Cochrane Database Syst Rev 4: CD000088.
53. Mari JJ, Streiner DL (1994) An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings. Psychol Med 24: 565-578.
54. Chien WT, Chan SW, Thompson DR (2006) Effects of a mutual support group for families of Chinese people with schizophrenia: 18-month follow-up. Br J Psychiatry 189: 41-49.
55. Chien WT, Wong KF (2007) A family psychoeducation group program for Chinese people with schizophrenia in Hong Kong. Psychiatr Serv 58: 1003-1006.
56. Pekkala E, Merinder L (2002) Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2: CD002831.
57. Ran MS, Xiang MZ, Chan CL, Leff J, Simpson P, et al. (2003) Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia-a randomised controlled trial. Soc Psychiatry Psychiatr Epidemiol 38: 69-75. (Pubitemid 37160767)
58. Li Z, Arthur D (2005) Family education for people with schizophrenia in Beijing, China: randomised controlled trial. Br J Psychiatry 187: 339-345. (Pubitemid 41442386)
59. Agara AJ, Onibi OE (2007) Effects of group psychoeducation (GPE) on compliance with scheduled clinic appointments in a neuro-psychiatric hospital in southwest Nigeria: a randomised control trial (RCT). Ann Acad Med Singapore 36: 272-275.
60. Maneesakorn S, Robson D, Gournay K, Gray R (2007) An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs 16: 1302-1312.
61. Zimmermann G, Favrod J, Trieu VH, Pomini V (2005) The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr Res 77: 1-9. (Pubitemid 40957056)
62. Turkington D, Sensky T, Scott J, Barnes TR, Nur U, et al. (2008) A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. Schizophr Res 98: 1-7. (Pubitemid 350245592)
63. Startup M, Jackson MC, Evans KE, Bendix S (2005) North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: two-year follow-up and economic evaluation. Psychol Med 35: 1307-1316. (Pubitemid 41264310)
64. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, et al. (2002) Psychological treatments in schizophrenia: I. meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 32: 763-782. (Pubitemid 34823330)
65. Bateman K, Hansen L, Turkington D, Kingdon D (2007) Cognitive behavioral therapy reduces suicidal ideation in schizophrenia: results from a randomized controlled trial. Suicide Life Threat Behav 37: 284-290. (Pubitemid 46974969)
66. Chafetz L, White M, Collins-Bride G, Cooper BA, Nickens J (2008) Clinical trial of wellness training: health promotion for severely mentally ill adults. J Nerv Ment Dis 196: 475-483.
67. Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, et al. (2001) Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care. Health Technol Assess 5: 1-75.
68. Marshall M, Lockwood A (2000) Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev 2: CD001089.
69. World Health Organization (2005) Atlas, mental health resources in the world. Geneva: WHO.
70. Walley J, Lawn JE, Tinker A, de Francisco A, Chopra M, et al. (2008) Primary health care: making Alma-Ata a reality. Lancet 372: 1001-1007.
71. Saxena S, Thornicroft G, Knapp M, Whiteford (2007) H. Resources for mental health: scarcity, inequity, and inefficiency. Lancet 370: 878-889.
72. Lancet Global Mental Health Group, Chisholm D, Flisher AJ, Lund C, Patel V, et al. (2007) Scale up services for mental disorders: a call for action. Lancet 370: 1241-1252. (Pubitemid 47503281)
73. Thara R, Padmavati R, Aynkran JR, John S (2008) Community mental health in India: a rethink. Int J Ment Health Syst 2: 11.
74. Kermode M, Bowen K, Arole S, Joag K, Jorm AF (2009) Community beliefs about treatments and outcomes of mental disorders: a mental health literacy survey in a rural area of Maharashtra, India. Public Health 123: 476-483.
75. Thornicroft G, Brohan E, Kassam A, Lewis-Holmes E (2008) Reducing stigma and discrimination: candidate interventions. Int J Ment Health Syst 2: 3.
76. Eaton WW, Thara R, Federman E, Tien A (1998) Remission and relapse in schizophrenia: the Madras Longitudinal Study. J Nerv Ment Dis 186: 357-363. (Pubitemid 28290027)
77. Razali SM, Mohd Yasin MA (2008) The pathway followed by psychotic patients to a tertiary health center in a developing country: a comparison with patients with epilepsy. Epilepsy Behav 13: 343-349.
78. Srinivasan TN, Thara R (1997) How do men with schizophrenia fare at work? A follow-up study from India. Schizophr Res 25: 149-154.
79. Bhugra D, McKenzie K (2003) Expressed emotion across cultures. Adv Psychiatr Treat 9: 342-348.
80. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, et al. (1992) Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 20: 1-97.
81. Schulsinger F, Jablensky A (1991) The national mental health programme in the United Republic of Tanzania. A report from WHO and DANIDA. Acta Psychiatr Scand Suppl 364: 1-132.
82. Susser E, Varma VK, Malhotra S, Conover S, Amador XF (1995) Delineation of acute and transient psychotic disorders in a developing country setting. Br J Psychiatry 167: 216-219. (Pubitemid 26194132)
83. Malhotra S, Malhotra S (2003) Acute and transient psychotic disorders: comparison with schizophrenia. Curr Psychiatry Rep 5: 178-186. (Pubitemid 38914993)
84. Somasundaram D, Thivakaran T, Bhugra D (2008) Possession states in Northern Sri Lanka. Psychopathology 41: 245-253. (Pubitemid 351685457)
85. Limosin F, Loze JY, Philippe A, Casadebaig F, Rouillon F (2007) Ten-year prospective follow-up of the mortality by suicide in schizophrenic patients. Schizophr Res 94: 23-28. (Pubitemid 47031602)
86. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ (2005) Schizophrenia and suicide: systematic review of risk factors. Brit J Psychiatry 187: 9-27. (Pubitemid 41002508)
87. Nordentoft M (2007) Prevention of suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups. Dan Med Bull 54: 306-369.
88. Carlborg A, Jokinen J, Jönsson EG, Nordstrom AL, Nördstrom P (2008) Long-term suicide risk in schizophrenia spectrum psychoses: survival analysis by gender. Arch Suicide Res 12: 347-351.
89. Lester D (2006) Sex differences in completed suicide by schizophrenic patients: a meta-analysis. Suicide Life Threat Behav 36: 50-56.
90. Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, et al. (2006) A national study of violent behaviour in persons with schizophrenia. Arch Gen Psychiatry 63: 490-499.
91. Meehan J, Flynn S, Hunt IM, Robinson J, Bickley H, et al. (2006) Perpetrators of homicide in schizophrenia: a national clinical survey in England and Wales. Psychiatr Serv 57: 1648-1651. (Pubitemid 44807047)
92. Lambertti JS (2007) Understanding and preventing criminal recidivism among adults with psychotic disorders. Psychiatr Serv 58: 773-781.
93. Volavka J, Laska EA, Baker S, Heisnser PC, Krivelevich I (1997) History of violent behavior and schizophrenia in different cultures. Brit J Psychiatry 171: 9-14.
94. Temmingh HS, Oosthuizen PP (2008) Pathways to care and treatment delays in first and multi episode psychosis. Findings from a developing country. Soc Psychiatry Psychiatr Epidemiol 43: 727-735.
95. Padmavathi R, Rajkumar S, Srinivasan TN (1998) Schizophrenic patients who were never treated-a study in an Indian urban community. Psychol Med 28: 1113-1117. (Pubitemid 28458467)
96. Kurihara T, Kato M, Reverger R, I Gusti Rai Tirta, Kashima H (2005) Never-treated patients with schizophrenia in the developing country of Bali. Schizophr Res 15: 307-313. (Pubitemid 41457271)
97. Chisholm D, Gureje O, Saldivia S, Villalón Calderón M, Wickremasinghe R, et al. (2008) Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ 86: 542-551. (Pubitemid 351931214)
98. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, et al. (2006) Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 367: 1193-1208.
99. Patel V, Araya R, Chatterjee S, Chisholm D, Cohen A, et al. (2007) Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet 370: 991-1005. (Pubitemid 47384829)
100. Thornicroft G, Tansella M (2004) Components of a modern mental health service: a pragmatic balance of community and hospital care: overview of systematic evidence. Br J Psychiatry 185: 283-290. (Pubitemid 39331329)
101. Nationa Institute for Health and Clinical Excellence (2009) NICE guidelines for schizophrenia. Available http://guidance.nice.org.uk/CG82. Accessed 22 August 2009.
102. Royal Australian and New Zealand College of Psychiatrists (2005) RANZCP clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 39: 1-30.
103. American Psychiatric Association (2006) Practice guideline for the treatment of patients with schizophrenia. In: Practice guideline for the treatment of psychiatric disorders. Washington (D.C.): APA.